These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1636 related items for PubMed ID: 22521613

  • 1. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Zhu L, Wei H, Wu Y, Yang S, Xiao L, Zhang J, Peng B.
    Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
    [Abstract] [Full Text] [Related]

  • 2. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M.
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [Abstract] [Full Text] [Related]

  • 3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X, Li Z, Yang Z, Zheng C, Jing J, Chen Y, Ye X, Lian X, Qiu W, Yang F, Tang J, Xiao J, Liu M, Luo J.
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [Abstract] [Full Text] [Related]

  • 4. Licorice isoliquiritigenin-encapsulated mesoporous silica nanoparticles for osteoclast inhibition and bone loss prevention.
    Sun X, Zhang J, Wang Z, Liu B, Zhu S, Zhu L, Peng B.
    Theranostics; 2019 Jun; 9(18):5183-5199. PubMed ID: 31410209
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H, Asagiri M, Kubota T, Oka K, Osada T, Sugiyama C, Saito H, Aoki K, Ohya K, Takayanagi H, Umezawa K.
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Alisol-B, a novel phyto-steroid, suppresses the RANKL-induced osteoclast formation and prevents bone loss in mice.
    Lee JW, Kobayashi Y, Nakamichi Y, Udagawa N, Takahashi N, Im NK, Seo HJ, Jeon WB, Yonezawa T, Cha BY, Woo JT.
    Biochem Pharmacol; 2010 Aug 01; 80(3):352-61. PubMed ID: 20412788
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of osteoclast differentiation and bone resorption by sauchinone.
    Han KY, Yang D, Chang EJ, Lee Y, Huang H, Sung SH, Lee ZH, Kim YC, Kim HH.
    Biochem Pharmacol; 2007 Sep 15; 74(6):911-23. PubMed ID: 17662251
    [Abstract] [Full Text] [Related]

  • 11. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
    Yuan FL, Xu RS, Jiang DL, He XL, Su Q, Jin C, Li X.
    Bone; 2015 Jun 15; 75():128-37. PubMed ID: 25708053
    [Abstract] [Full Text] [Related]

  • 12. Anti-osteoclastogenic activity of isoliquiritigenin via inhibition of NF-κB-dependent autophagic pathway.
    Liu S, Zhu L, Zhang J, Yu J, Cheng X, Peng B.
    Biochem Pharmacol; 2016 Apr 15; 106():82-93. PubMed ID: 26947453
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity.
    Yip KH, Zheng MH, Feng HT, Steer JH, Joyce DA, Xu J.
    J Bone Miner Res; 2004 Nov 15; 19(11):1905-16. PubMed ID: 15476591
    [Abstract] [Full Text] [Related]

  • 15. Inhibitory effects of Stewartia koreana on osteoclast differentiation and bone resorption.
    Park CK, Kim HJ, Kwak HB, Lee TH, Bang MH, Kim CM, Lee Y, Chung DK, Baek NI, Kim J, Lee ZH, Kim HH.
    Int Immunopharmacol; 2007 Dec 05; 7(12):1507-16. PubMed ID: 17920527
    [Abstract] [Full Text] [Related]

  • 16. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P, Tu Q, Chen J.
    J Bone Miner Res; 2005 Sep 05; 20(9):1669-79. PubMed ID: 16059638
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of osteoclast differentiation and bone resorption by rotenone, through down-regulation of RANKL-induced c-Fos and NFATc1 expression.
    Kwak HB, Lee BK, Oh J, Yeon JT, Choi SW, Cho HJ, Lee MS, Kim JJ, Bae JM, Kim SH, Kim HS.
    Bone; 2010 Mar 05; 46(3):724-31. PubMed ID: 19900598
    [Abstract] [Full Text] [Related]

  • 18. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
    Nepal M, Choi HJ, Choi BY, Yang MS, Chae JI, Li L, Soh Y.
    Eur J Pharmacol; 2013 Sep 05; 715(1-3):96-104. PubMed ID: 23791609
    [Abstract] [Full Text] [Related]

  • 19. A novel small molecule, NecroX-7, inhibits osteoclast differentiation by suppressing NF-κB activity and c-Fos expression.
    Kim HJ, Yoon KA, Lee MK, Kim SH, Lee IK, Kim SY.
    Life Sci; 2012 Nov 02; 91(19-20):928-34. PubMed ID: 23000100
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
    Odkhuu E, Koide N, Haque A, Tsolmongyn B, Naiki Y, Hashimoto S, Komatsu T, Yoshida T, Yokochi T.
    Immunol Lett; 2012 Feb 29; 142(1-2):34-40. PubMed ID: 22193059
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 82.